USA flag logo/image

An Official Website of the United States Government

Therapeutic Ultrasound Contrast Agent Dynamics Modeling SBIR Phase II

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
80226
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
EB005139
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Dynaflow, Inc.
10621-J Iron Bridge Rd. Jessup, MD 20794-9381
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2009
Title: Therapeutic Ultrasound Contrast Agent Dynamics Modeling SBIR Phase II
Agency: HHS
Contract: 2R44EB005139-02A1
Award Amount: $749,397.00
 

Abstract:

DESCRIPTION (provided by applicant): Target drug and gene delivery are rapidly emerging applications for ultrasound contrast agents since they reduce potential deleterious side effects to healthy tissue and minimize the overall dose needed. Development of new contrast agents requires a good understanding of the effect of the properties of the viscous material of the shell and of the acoustic field on the dynamics of the agent and on the mechanism of breakup of the shell. A novel numerical code, which enable s modeling of non-spherical contrast agent's dynamics acoustic waves and nearby boundaries and tissues is proposed. This model, whose feasibility was demonstrated in Phase I, will allow us to accurately predict the necessary conditions for breakup. In Phas e I we coupled a Boundary Element Method solver and a Navier-Stokes solver and demonstrated 3D modeling of viscous thick shelled contrast agent including in the presence of rigid walls, and identified the mechanisms for shell breakup due to non-spherical d eformations. In the Phase II study, we will complete, improve and expand the capabilities of the model to simulate viscoelastic shell material properties and simulate multiple contrast agents' interactions with deformable boundaries such as blood cells, ti ssues, and blood vessels. We will also validate the developed model experimentally using both a scaled-up test for visualization and actual contrast agents for breakup limit confirmation. PUBLIC HEALTH RELEVANCE: Success of this research will help pharmace utical companies develop safer and more efficient drug and gene delivery agents. These agents are especially attractive to chemotherapy treatment because they can greatly reduce deleterious side effects to healthy tissue caused by many chemotherapy drugs a nd minimize the overall dose needed.

Principal Investigator:

Chaotsung Hsiao
3046043688

Business Contact:

Georges L. Chahine
yuko@dynaflow-inc.com
Small Business Information at Submission:

DYNAFLOW, INC.
10621-J IRON BRIDGE ROAD JESSUP, MD 20794

EIN/Tax ID: 521573410
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No